Author(s): Engel, Amber R ; Vasconcelos, Pedro Fernando da Costa ; McArthur, Monica A ; Barrett, Alan D. T
Date: 2016
Origin: Oasisbr
Subject(s): Febre Amarela / preven??o & controle; Vacina contra Febre Amarela / classifica??o; V?rus da Febre Amarela / classifica??o; V?rus da Febre Amarela / isolamento & purifica??o
University of Texas Medical Branch. Department of Pathology. Galveston, TX, USA.
Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.
University Of Texas Medical Branch. Department of Microbiology and Immunology. Galveston, TX, USA.
The University of Texas Medical Branch. Department of Pathology. Galveston, TX, USA / The University of Texas Medical Branch. Department of Microbiology and Immunology. Galveston, TX, USA / The University of Texas Medical Branch. Sealy Center for Vaccine Development. Galveston, TX, USA / The University of Texas Medical Branch. Center for Biodefense and Emerging Infectious Diseases. Galveston, TX, USA.
Although the live attenuated yellow fever (YF) 17D vaccine is considered to be one of the safest vaccines in the world today, several cases of disease associated with administration of the vaccine have been reported, including YF vaccine-associated viscerotropic disease (YF-VAVD), which was first described in 1996. All YF-VAVD isolates sequenced to date have shown very little genomic change when compared to their parental vaccine strains. In this study, we report the characterization of an isolate, BeH291597 (Brazil75), from a 1975 fatal case of YF-VAVD in Brazil. Comparison of Brazil75 with the genomic sequence of the parental 17DD vaccine strain revealed two amino acid substitutions (at positions M-49 and NS4B-240) that were unique to Brazil75. Although still a rare occurrence, this isolate suggests that YF-VAVD has been present much longer than previously recognized.
